The Combination of Sorafenib and PGV-1 Inhibits the Proliferation of Hepatocellular Carcinoma Through c-Myc Suppression in an Additive Manner: In Vitro Studies

• Main Authors: Dhania Novitasari (Author), Ikuko Nakamae (Author), Noriko Yoneda-Kato (Author), Jun-ya Kato (Author), Yoshitaka Hippo (Author), Yusuke Suenaga (Author), Dyaningtyas Dewi Pamungkas Putri (Author), Edy Meiyanto (Author), Muthi' Ikawati (Author)
• Format: Book
• Published: Wiley, 2024-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Hepatocellular carcinoma (HCC) is one of the most aggressive types of liver cancer, and it is frequently associated with upregulated c-Myc expression. Sorafenib (Sor) is commonly used to treat HCC, but many patients experienced mild to severe side effects due to prolonged Sor treatment during therap...